COMMUNIQUÉS West-GlobeNewswire

NextCure Provides Business Update and Reports Full Year 2024 Financial Results
06/03/2025
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 Cash of approximately $68.6 million expected to fund [...]
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
06/03/2025
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
06/03/2025
– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company [...]
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
06/03/2025
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus ( HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET [...]
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results
06/03/2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
06/03/2025
No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications. SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. ( [...]
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients [...]
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
06/03/2025
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 [...]
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
06/03/2025
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX [...]
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
06/03/2025
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/03/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mars 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général [...]
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
06/03/2025
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs [...]
Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion
06/03/2025
Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage thérapeutique des MICI : Le point de vue des leaders d’opinion NANTES, France, 6 mars 2025, 18 heures – OSE Immunotherapeutics a récemment [...]
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
06/03/2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Février 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/03/2025
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
protocols.io Integrates with eLabNext’s Digital Lab Platform to Ease Access to and Track Protocol Use in Laboratories
06/03/2025
BOSTON, March 06, 2025 (GLOBE NEWSWIRE) -- Today, protocols.io , a platform that enables academic and industry researchers to record and share up-to-date methods for research, announced that, under eLabNext leadership, [...]
New national survey finds most Americans unaware concussions are traumatic brain injuries
06/03/2025
New national survey shows public misconceptions about brain injuries persist and highlight need for education Survey Highlights: 81% of adults in the U.S. do not recognize concussions as traumatic brain injuries. While [...]
Spectral AI Completes Three Device Installations in Australia
06/03/2025
DALLAS, March 06, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”) , developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and [...]
New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
06/03/2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) [...]

Pages